EUVIMEDEUVIMED entdecken
Crossref

Long‐Term Medication‐Induced Weight Change Across Common Antiseizure Medications: A Target Trial Emulation Study

Han Yu iD, Jessica G Young, Joshua Petimar iD, Sheryl L Rifas-Shiman, Matthew F Daley, William J Heerman iD, David M Janicke iD, W Schuyler Jones, Takuya Kawahara, Kristina H Lewis iD, Pi-I D Lin, Sengwee Toh und 2 weitere

Obesity · 2025-12 · 33 (12) · 2355-2364

DOI: 10.1002/oby.24362 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Obesity, online erschienen am 05.10.2025. Verfasst von Han Yu und 13 weiteren Autor:innen. Beteiligte Einrichtung: Department of Population Medicine, Harvard Medical School & Harvard Pilgrim Health Care Institute, Boston, Massachusetts, USA. Hauptthemen laut MEDLINE: Anticonvulsants, Weight Gain, Weight Loss, Epilepsy. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 45 Literaturangaben. Gefördert von: NIDDK NIH HHS, National Institute of Diabetes and Digestive and Kidney Diseases.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objective

To estimate long‐term weight change after initiation and adherence to commonly used antiseizure medications (ASMs) and examine differences in weight change across ASMs compared to topiramate.

Methods

We included 52,309 adult patients who initiated ASMs, applied a target trial emulation approach to control time‐varying confounding and selection bias, and examined the long‐term comparative effects on weight change after initiating and adhering to different ASMs at 6 and 12 months post initiation.

Results

The most commonly initiated ASM was topiramate (41.2%). In comparison to topiramate, we estimated higher 6‐month weight change under initiation and adherence to levetiracetam 0.94 kg (95% CI 0.20, 1.64), lamotrigine 1.44 kg (0.74, 1.99), valproate 2.42 kg (1.71, 2.88), carbamazepine 1.32 kg (0.46, 2.16), and oxcarbazepine 1.74 kg (0.85, 2.71), with similar results at 12 months and in sensitivity and subgroup analyses. These results were driven mostly by weight loss with use of topiramate rather than weight gain with use of other ASMs. Results were similar though attenuated when accounting for medication initiation only.

Conclusions

Topiramate was associated with weight loss at 6 and 12 months under either initiation and subsequent adherence or initiation‐only effects; other medications were associated with higher weight change. These results provided important information to help with decision‐making regarding ASM initiation.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

AnticonvulsantsWeight GainWeight LossEpilepsyHumansMaleTopiramateFemaleMiddle AgedAdultFructoseLamotrigineLevetiracetamCarbamazepineValproic AcidAgedTriazines

Stichwörter der Autor:innen

antiseizure medicationobesitytarget trial emulationweight change

Substanzen

AnticonvulsantsTopiramateFructoseLamotrigineLevetiracetamCarbamazepineValproic AcidTriazines

Autor:innen und Institutionen

  • Department of Population Medicine, Harvard Medical School & Harvard Pilgrim Health Care Institute, Boston, Massachusetts, USA.
  • Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, Massachusetts, USA.
  • Institute for Health Research, Kaiser Permanente Colorado, Denver, Colorado, USA.
  • Department of Pediatrics, Vanderbilt University Medical Center, Nashville, Tennessee, USA.
  • Department of Clinical and Health Psychology, College of Public Health and Health Professions, University of Florida, Gainesville, Florida, USA.
  • Division of Cardiology, Duke University Department of Medicine, Durham, North Carolina, USA.

ORCID-Profile: Han Yu, Joshua Petimar, William J Heerman, David M Janicke, Kristina H Lewis

Förderung

  • NIDDK NIH HHS
  • National Institute of Diabetes and Digestive and Kidney Diseases

Zitieren

APA

Yu, H., Young, J. G., Petimar, J., Rifas-Shiman, S. L., Daley, M. F., Heerman, W. J., Janicke, D. M., Jones, W. S., Kawahara, T., Lewis, K. H., Lin, P. D., Toh, S., Weisholtz, D. S., & Block, J. P. (2025). Long‐Term Medication‐Induced Weight Change Across Common Antiseizure Medications: A Target Trial Emulation Study. Obesity, 33(12), 2355-2364. https://doi.org/10.1002/oby.24362

Vancouver

Yu H, Young JG, Petimar J, Rifas-Shiman SL, Daley MF, Heerman WJ, et al. Long‐Term Medication‐Induced Weight Change Across Common Antiseizure Medications: A Target Trial Emulation Study. Obesity. 2025;33(12):2355-2364. doi:10.1002/oby.24362

BibTeX
@article{Yu2025,
  author = {Yu, Han and Young, Jessica G and Petimar, Joshua and Rifas-Shiman, Sheryl L and Daley, Matthew F and Heerman, William J and Janicke, David M and Jones, W Schuyler and Kawahara, Takuya and Lewis, Kristina H and Lin, Pi-I D and Toh, Sengwee and Weisholtz, Daniel S and Block, Jason P},
  title = {Long‐Term Medication‐Induced Weight Change Across Common Antiseizure Medications: A Target Trial Emulation Study},
  journal = {Obesity},
  year = {2025},
  volume = {33},
  number = {12},
  pages = {2355--2364},
  doi = {10.1002/oby.24362}
}
Kostenlos starten →